Core Viewpoint - The company announced the appointment of Mr. Liu Hongkang as a non-executive director, effective from February 12, 2026, until the end of the second board's term [1] Group 1 - The appointment was approved by shareholders at a special general meeting [1] - The board meeting held on January 27, 2026, reviewed and approved Mr. Liu's appointment, pending shareholder approval [1] - Mr. Liu will also serve as a member of the board's audit committee and strategic development committee [1]

BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 百奧賽圖（北京）醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2315） 董事名單與其角色和職能 百奧賽圖（北京）醫藥科技股份有限公司董事會（「董事會」）成員載列如下： 執行董事 沈月雷博士 （董事長、首席執行官兼總經理） 倪健博士 非執行董事 劉弘康先生 周可祥博士 張蕾娣女士 獨立非執行董事 華風茂先生 喻長遠博士 梁曉燕女士 職工董事 李妍女士 1 董事會下設四個董事會委員會。各董事會成員在這些委員會中所擔任的職位載列 如下： | | 審計委員會 | 薪酬與考核 | | 戰略發展 | | --- | --- | --- | --- | --- | | | | 委員會 | 提名委員會 | 委員會 | | 沈月雷博士 | | | M | C | | 倪健博士 | | M | | | | 劉弘康先生 | M | | | M | | 周可祥博士 | | | | M | | 張蕾娣女士 | | | | M | | 華風茂先生 | M | C | M | | | 喻長遠博士 | M | M ...

Core Viewpoint - The company Baosai Tu-B (02315) has announced the appointment of Mr. Liu Hongkang as a non-executive director, effective from February 12, 2026, until the end of the second board's term [1] Group 1 - The appointment of Mr. Liu was approved by shareholders at an extraordinary general meeting [1] - Mr. Liu will also serve as a member of the board's audit committee and strategic development committee following his appointment [1] - The board meeting to approve Mr. Liu's appointment is scheduled for January 27, 2026, pending shareholder approval [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 百奧賽圖（北京）醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2315） (1)於2026年2月12日舉行之 2026年第一次臨時股東會投票表決結果； (2)委任非執行董事；及 (3)董事會委員會組成變更 臨時股東會投票表決結果 茲提述百奧賽圖（北京）醫藥科技股份有限公司（「本公司」），日期為2026年1月27 日的2026年第一次臨時股東會通告（「該通告」）及通函（「該通函」）。除文義另有 所指外，本公告所用詞彙與該通告及該通函所界定者具有相同涵義。 董事會謹此宣佈，本公司已於2026年2月12日（星期四）下午二時正（香港時間）假 座中國北京市大興區大興生物醫藥產業基地寶參南街12號院會議室以現場會議結 合網上虛擬會議的方式舉行臨時股東會。臨時股東會乃根據中國公司法及公司章 程 ...

Group 1 - The stock price of Reborn Biotech (06938.HK) increased by 13.65% [1] - WuXi Biologics (02269.HK) saw a rise of 4.83% in its stock price [1] - Baosai Tu-B (02315.HK) experienced a stock price increase of 3.88% [1] - WuXi AppTec (02359.HK) had a stock price growth of 3.15% [1]

Core Viewpoint - The company BaiO Saite-B (02315) has seen a significant stock increase of over 6% following the release of its 2025 performance forecast, indicating strong growth potential in revenue and net profit [1] Group 1: Financial Performance - BaiO Saite-B forecasts annual revenue for 2025 to be approximately 1.369 billion to 1.389 billion yuan, representing a year-on-year growth of 39.61% to 41.65% [1] - The expected net profit attributable to shareholders is projected to be around 162 million to 182 million yuan, showing a substantial year-on-year increase of 384.26% to 443.88% [1] Group 2: Market Position and Growth Drivers - According to Guolian Minsheng Securities, the company's strong performance is attributed to its innovative advantages in model animals and preclinical CRO business, as well as the antibody platform supported by the "Thousand Mice and Ten Thousand Antibodies" initiative [1] - The company has established partnerships with several leading domestic and international pharmaceutical companies since 2025, and multiple pipelines have received IND approvals, which are expected to generate milestone payments and further enhance growth potential [1]

Group 1 - MSCI announced its quarterly index adjustments for February 2026, effective after the market close on February 27 [2][3] - The MSCI Global Small Cap Index will include 21 new stocks from the China region, such as Anjuke Food (603345), AutoHome (ATHM.US), and Baiaosaitu (02315) [2][3] - The adjustments also include the addition of stocks from Hong Kong, such as Champion REIT (02778) and Longjiang Life Science Technology (00755) [3][4] Group 2 - Stocks removed from the MSCI Global Small Cap Index include Yasheng Service (03319), BOE Technology Group (00710), and Chaince Digital (CD.US) [2][3] - In Hong Kong, stocks like Cafe de Coral (00341) and SuperX AI (SUPX.US) were also removed from the index [4]

Core Viewpoint - BaiOScitech-B (02315.HK) experienced a significant increase in stock price, rising over 6% in the afternoon trading session on February 11, reaching a price of 52.95 HKD with a trading volume of 34.03 million HKD [1] Summary by Category - **Stock Performance** - The stock price of BaiOScitech-B rose by 6.33% to 52.95 HKD [1] - The trading volume was reported at 34.03 million HKD [1]

Core Viewpoint - Baosai Tu-B (02315) has shown a significant increase in stock price, rising over 6% following the release of its 2025 performance forecast, indicating strong growth potential in revenue and net profit [1] Group 1: Financial Performance - The company forecasts a revenue of approximately 1.369 billion to 1.389 billion yuan for 2025, representing a year-on-year growth of 39.61% to 41.65% [1] - Expected net profit attributable to shareholders is projected to be between 162 million to 182 million yuan, reflecting a substantial year-on-year increase of 384.26% to 443.88% [1] Group 2: Business Drivers - Guolian Minsheng Securities highlights the company's innovative advantages in model animals and preclinical CRO business, as well as the strengths of its antibody platform supported by the "Thousand Mice, Ten Thousand Antibodies" initiative [1] - Since 2025, the company has established external licensing agreements with several leading domestic and international pharmaceutical companies, and multiple pipelines have received IND approvals, which are expected to contribute to milestone payments and further revenue growth [1]

Core Viewpoint - The stock of Baiaosaitu-B (02315) rose over 6% following the release of its 2025 performance forecast, indicating strong growth potential driven by external licensing agreements and innovative business models [1] Group 1: Financial Performance - Baiaosaitu expects to achieve revenue between 1.369 billion to 1.389 billion yuan for the year 2025, representing a year-on-year growth of 39.61% to 41.65% [1] - The company anticipates a net profit attributable to shareholders of approximately 162 million to 182 million yuan, reflecting a significant year-on-year increase of 384.26% to 443.88% [1] Group 2: Business Drivers - The strong performance is attributed to the innovative advantages in model animals and preclinical CRO (Contract Research Organization) business, as well as the antibody platform supported by the "Thousand Mice, Ten Thousand Antibodies" initiative [1] - Since 2025, the company has established external licensing agreements with several leading domestic and international pharmaceutical companies, which is expected to enhance revenue through milestone payments as the licensed pipelines progress [1]